To pave the way for the clinical investigation on dalpiciclib in HNMM, we first evaluated the in vivo and in vitro anti-tumor efficacy of dalpiciclib using the stably passaged HNMM-PDX and HNMM-PDC. Here, PDC is linked to neoplasm.